Epigenomics' Preliminary 2013 Revenues Improve 60 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today announced preliminary revenue growth of 60 percent for full-year 2013.

Revenues for 2013 increased to €1.6 million ($2.2 million) from €1.0 million in 2012 on a strategic collaboration with BioChain in China and increased R&D service fees, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.